Core Viewpoint - Autonomix Medical, Inc. is enhancing its intellectual property portfolio with the issuance of U.S. Patent No. 12,295,646, which relates to a smart torquer device aimed at improving intravascular procedures, positioning the company for significant opportunities in a multi-billion-dollar market [1][2]. Group 1: Intellectual Property and Market Position - The company has over 80 issued patents and 40 pending applications, establishing a strong IP portfolio in nerve-sensing and modulation technologies [1]. - The newly issued '646 patent is designed to improve the manipulation of intravascular devices during minimally invasive procedures, integrating electronic components for better mechanical control and data communication [1][3]. - The smart torquer technology is expected to enhance control and signal integration in intravascular procedures, facilitating expansion into high-growth areas such as cardiology, neurosurgery, and interventional radiology [2]. Group 2: Technology and Applications - Autonomix's technology platform includes a catheter-based microchip sensing array that can detect and differentiate neural signals with greater sensitivity than existing technologies [4][6]. - The proprietary RF ablation technology allows for precision-guided interventions targeting specific nerves, which can address various diseases, including chronic pain and hypertension [4][7]. - Initial development efforts are focused on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [7].